

Patient Characteristics, Testing and Treatment Patterns, and Outcomes in *EGFR*-mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study

Cliff Molife¹, Katherine B. Winfree¹, Hollie Bailey², Yulia D'yachkova^{3*}, Cameron Forshaw², Sangmi Kim⁴, Kaisa-Leena Taipale⁵, Tarun Puri⁶

1. Value, Evidence, and Outcomes, Eli Lilly and Company, Indianapolis, IN, USA
2. Adelphi Real World, Bollington, UK
3. Statistics, Eli Lilly and Company, Vienna, Austria
4. Global Patient Safety – Pharmacoepidemiology, Eli Lilly and Company, Indianapolis, IN, USA
5. Value, Evidence, and Outcomes – International, Eli Lilly and Company, Helsinki, Finland
6. Lilly International Medical Affairs Oncology, Eli Lilly and Company, Gurgaon, Haryana, India

*Former employee of Eli Lilly and Company.

Corresponding Author:

Cliff Molife, PhD
Senior Advisor
Value, Evidence, and Outcomes – Oncology
Eli Lilly and Company
Lilly Corporate Center,
Indianapolis, IN, 46285, USA
Phone: +1 3172772965
Email: molife_cliff@lilly.com

Supplementary Tables

Supplementary Table S1. Physician Characteristics – Overall and by Country

Physician Characteristics	Overall (n=542)	US (n=71)	BR (n=53)	UK (n=51)	IT (n=49)	FR (n=51)	ES (n=50)	DE (n=50)	EU5 [#] (n=251)	TW (n=51)	JP (n=116)
Specialty											
Clinical oncologist	16 (3.0)	0	0	16 (31.0)	0	0	0	0	16 (6.0)	0	0
Medical oncologist	333 (61.0)	60 (85.0)	48 (91.0)	35 (69.0)	44 (90.0)	36 (71.0)	50 (100.0)	32 (64.0)	197 (79.0)	19 (37.0)	9 (8.0)
Pulmonologist	170 (31.0)	11 (15.0)	5 (9.0)	0	5 (10.0)	15 (29.0)	0	18 (36.0)	38 (15.0)	32 (63.0)	84 (72.0)
Respiratory surgeon	23 (4.0)	0	0	0	0	0	0	0	0	0	23 (20.0)
Hospital type	n=454	n=56	n=49	n=40	n=37	n=43	n=48	n=24	n=192	n=47	n=110
Community	50 (11.0)	30 (54.0)	5 (10.0)	0	3 (8.0)	4 (9.0)	0	8 (33.0)	15 (8.0)	0	0
General	168 (37.0)	0	30 (61.0)	10 (25.0)	20 (54.0)	22 (51.0)	2 (4.0)	10 (42.0)	64 (33.0)	30 (64.0)	44 (40.0)
Public	28 (6.0)	0	0	0	0	0	0	0	0	0	28 (25.0)
University	201 (44.0)	26 (46.0)	10 (20.0)	30 (75.0)	14 (38.0)	16 (37.0)	46 (96.0)	5 (21.0)	111 (58.0)	17 (36.0)	37 (34.0)
Other	7 (2.0)	0	4 (8.0)	0	0	1 (2.0)	0	1 (4.0)	2 (1.0)	0	1 (1.0)
Percentage of time spent, %											
CCC	16.0	19.0	23.0	38.0	26.0	14.0	4.0	17.0	20.0	10.0	6.0
Hospital											
Public	44.0	8.0	11.0	50.0	61.0	73.0	88.0	41.0	62.0	25.0	48.0
Private	23.0	21.0	28.0	3.0	7.0	11.0)	1.0	2.0	5.0	65.0	43.0
Consulting/office											
Public	6.0	3.0	4.0	8.0	4.0	0	4.0	38.0	11.0	0	0
Private	11.0)	50.0	34.0	2.0	2.0	2.0	3.0	3.0	2.0	0	2.0
Percentage of time in performing academic duties%	13.0	11.0	9.0	15.0	8.0	9.0	14.0	11.0	11.0	24.0	14.0

All data are presented as n (%), unless specified.

^aIncludes the UK, IT, FR, ES, and DE.

BR Brazil, CCC comprehensive care center, DE Germany, ES Spain, EU5 5 countries from the European Union, FR France, IT Italy; JP=Japan; TW=Taiwan; UK=United Kingdom; US=United States

Supplementary Table S2. Tumor Staging at Different Timepoints – Overall and By Country

	Overall (n=2857)	US (n=422)	BR (n=313)	UK (n=279)	IT (n=287)	FR (n=285)	ES (n=302)	DE (n=284)	EU5 ^a (n=1437)	TW (n=390)	JP (n=295)
Staging at advanced diagnosis											
Stage IIIB	356 (13.0)	66 (16.0)	84 (27.0)	5 (2.0)	27 (9.0)	14 (5.0)	4 (1.0)	87 (31.0)	137 (10.0)	37 (10.0)	32 (11.0)
Stage IIIC	182 (6.0)	36 (9.0)	31 (10.0)	3 (1.0)	19 (7.0)	22 (8.0)	6 (2.0)	39 (14.0)	89 (6.0)	13 (3.0)	13 (4.0)
Stage IVA	867 (30.0)	136 (32.0)	98 (31.0)	64 (23.0)	75 (26.0)	82 (29.0)	65 (22.0)	82 (29.0)	368 (26.0)	158 (41.0)	107 (36.0)
Stage IVB	1432 (50.0)	184 (44.0)	95 (30.0)	207 (74.0)	152 (53.0)	166 (58.0)	227 (75.0)	76 (27.0)	828 (58.0)	182 (47.0)	143 (49.0)
Unknown/not assessed	20 (1.0)	0	5 (2.0)	0	14 (5.0)	1 (<1.0)	0	0	15 (1.0)	0	0
Staging at initiation of 1L treatment after advanced diagnosis											
Stage IIIB	268 (9.0)	51 (12.0)	48 (15.0)	3 (1.0)	21 (7.0)	9 (3.0)	2 (1.0)	79 (28.0)	114 (8.0)	33 (9.0)	22 (8.0)
Stage IIIC	211 (7.0)	44 (10.0)	44 (14.0)	3 (1.0)	22 (8.0)	22 (8.0)	6 (2.0)	45 (16.0)	98 (7.0)	13 (3.0)	12 (4.0)
Stage IVA	892 (31.0)	138 (33.0)	111 (36.0)	64 (23.0)	77 (27.0)	85 (30.0)	62 (21.0)	82 (29.0)	370 (26.0)	161 (41.0)	112 (38.0)
Stage IVB	1468 (51.0)	184 (44.0)	107 (34.0)	209 (75.0)	157 (55.0)	169 (59.0)	232 (77.0)	78 (28.0)	845 (59.0)	183 (47.0)	149 (51.0)
Unknown/not assessed	18 (1.0)	5 (1.0)	3 (1.0)	0	10 (4.0)	0	0	0	10 (1.0)	0	0
Staging at initiation of current therapy											
Stage IIIB	222 (8.0)	46 (11.0)	39 (13.0)	3 (1.0)	13 (5.0)	7 (3.0)	2 (1.0)	61 (22.0)	86 (6.0)	31 (8.0)	20 (7.0)
Stage IIIC	218 (8.0)	49 (12.0)	40 (13.0)	2 (1.0)	26 (9.0)	20 (7.0)	5 (2.0)	54 (19.0)	107 (7.0)	11 (3.0)	11 (4.0)
Stage IVA	885 (31.0)	140 (33.0)	110 (35.0)	58 (21.0)	81 (28.0)	88 (31.0)	61 (20.0)	87 (31.0)	375 (26.0)	156 (40.0)	104 (35.0)
Stage IVB	1523 (53.-)	186 (44.0)	121 (39.0)	216 (77.0)	163 (57.0)	170 (60.0)	234 (78.0)	81 (29.0)	864 (60.0)	192 (49.0)	160 (54.0)
Unknown/not assessed	9 (<1.0)	1 (<1.0)	3 (1)	0	4 (1.0)	0	0	1 (0.0)	5 (<1.0)	0	0
Staging at current consultation											
Stage IIIB	210 (7.0)	41 (10.0)	35 (11.0)	3 (1.0)	14 (5.0)	6 (2.0)	2 (1.0)	60 (21.0)	85 (6.0)	31 (8.0)	18 (6.0)
Stage IIIC	214 (8.0)	51 (12.0)	33 (11.0)	2 (1.0)	26 (9.0)	21 (7.0)	5 (2.0)	52 (18.0)	106 (7.0)	11 (3.0)	13 (4.0)
Stage IVA	895 (31.0)	142 (34.0)	120 (38.0)	57 (20.0)	84 (29.0)	87 (31.0)	61 (20.0)	89 (31.0)	378 (26.0)	152 (39.0)	103 (35.0)
Stage IVB	1538 (54.0)	188 (45.0)	125 (40.0)	217 (78.0)	163 (57.0)	171 (60.0)	234 (78.0)	83 (29.0)	868 (60.0)	196 (50.0)	161 (55.0)
Unknown/not assessed	0	0	0	0	0	0	0	0	0	0	0

All data are presented as n (%).

^aIncludes the UK, IT, FR, ES, and DE.

1L first line, *BR* Brazil, *DE* Germany, *ES* Spain, *EU5* 5 countries from the European Union, *FR* France, *IT* Italy, *JP* Japan, *TW* Taiwan, *UK* United Kingdom, *US* United States

Supplementary Table S3. ECOG Status at Different Timepoints – Overall and By Country

Country	ECOG Status	Adv. Dx	Initiation of Tx after Adv. Dx	Initiation of Current Tx	Current Consultation
Overall (n=2857)	0	776 (27.0)	732 (26.0)	688 (24.0)	810 (28.0)
	1	1412 (49.0)	1468 (51.0)	1456 (51.0)	1383 (48.0)
	2	458 (16.0)	436 (15.0)	473 (17.0)	407 (14.0)
	3	105 (4.0)	116 (4.0)	123 (4.0)	123 (4.0)
	4	73 (3.0)	81 (3.0)	96 (3.0)	116 (4.0)
	Unknown/not assessed	29 (1.0)	24 (1.0)	21 (1.0)	18 (1.0)
US (n=422)	0	81 (19.0)	78 (19.0)	72 (17.0)	75 (18.0)
	1	220 (52.0)	221 (52.0)	212 (50.0)	209 (50.0)
	2	57 (14.0)	54 (13.0)	72 (17.0)	73 (17.0)
	3	22 (5.0)	23 (6.0)	20 (5.0)	18 (4.0)
	4	37 (9.0)	37 (9.0)	41 (10.0)	42 (10.0)
	Unknown/not assessed	5 (1.0)	9 (2.0)	5 (1.0)	5 (1.0)
BR (n=313)	0	43 (14.0)	39 (13.0)	37 (12.0)	49 (16.0)
	1	138 (44.0)	135 (43.0)	129 (41.0)	120 (38.0)
	2	91 (29.0)	81 (26.0)	77 (25.0)	64 (20.0)
	3	28 (9.0)	38 (12.0)	41 (13.0)	35 (11.0)
	4	8 (3.0)	16 (5.0)	26 (8.0)	41 (13.0)
	Unknown/not assessed	5 (2.0)	4 (1.0)	3 (1.0)	4 (1.0)
UK (n=279)	0	60 (22.0)	57 (20.0)	56 (20.0)	77 (28.0)
	1	177 (63.0)	182 (65.0)	183 (66.0)	167 (60.0)
	2	35 (13.0)	32 (12.0)	32 (12.0)	27 (10.0)
	3	2 (1.0)	3 (1.0)	3 (1.0)	3 (1.0)
	4	5 (2.0)	5 (2.0)	5 (2.0)	5 (2.0)
	Unknown/not assessed	0	0	0	0
IT (n=287)	0	121 (42.0)	123 (43.0)	120 (42.0)	130 (45.0)
	1	109 (38.0)	110 (38.0)	108 (38.0)	96 (33.0)
	2	28 (10.0)	29 (10.0)	26 (9.0)	25 (9.0)
	3	8 (3.0)	10 (4.0)	18 (6.0)	21 (7.0)
	4	6 (2.0)	7 (2.0)	9 (3.0)	9 (3.0)

	Unknown/not assessed	15 (5.0)	8 (3.0)	6 (2.0)	6 (2.0)
FR (n=285)	0	70 (25.0)	61 (21.0)	49 (17.0)	61 (21.0)
	1	149 (52.0)	161 (57.0)	172 (60.0)	170 (60.0)
	2	57 (20.0)	55 (19.0)	55 (19.0)	44 (15.0)
	3	6 (2.0)	7 (3.0)	7 (3.0)	7 (3.0)
	4	1 (<1.0)	1 (<1.0)	2 (1.0)	3 (1.0)
	Unknown/not assessed	1 (<1.0)	0	0	0
ES (n=302)	0	49 (16.0)	45 (15.0)	50 (17.0)	83 (28.0)
	1	188 (62.0)	194 (64.0)	192 (64.0)	188 (62.0)
	2	60 (20.0)	58 (19.0)	54 (18.0)	24 (8.0)
	3	1 (<1.0)	1 (<1.0)	2 (1.0)	2 (1.0)
	4	4 (1.0)	4 (1.0)	4 (1.0)	5 (2.0)
	Unknown/not assessed	0	0	0	0
DE (n=284)	0	93 (33.0)	73 (26.0)	51 (18.0)	59 (21.0)
	1	126 (44.0)	132 (47.0)	135 (48.0)	124 (44.0)
	2	47 (17.0)	59 (21.0)	75 (26.0)	76 (27.0)
	3	15 (5.0)	17 (6.0)	16 (6.0)	22 (8.0)
	4	0	0	0	0
	Unknown/not assessed	3 (1.0)	3 (1.0)	7 (3.0)	3 (1.0)
EU5^a (n=1437)	0	393 (27.0)	359 (25.0)	326 (23.0)	410 (29.0)
	1	749 (52.0)	779 (54.0)	790 (55.0)	745 (52.0)
	2	227 (16.0)	233 (16.0)	242 (17.0)	196 (14.0)
	3	32 (2.0)	38 (3.0)	46 (3.0)	55 (4.0)
	4	16 (1.0)	17 (1.0)	20 (1.0)	22 (2.0)
	Unknown/not assessed	19 (1.0)	11 (1.0)	13 (1.0)	9 (1.0)
TW (n=390)	0	99 (25.0)	101 (26.0)	105 (27.0)	126 (32.0)
	1	202 (52.0)	218 (56.0)	213 (55.0)	193 (50.0)
	2	65 (17.0)	51 (13.0)	56 (14.0)	56 (14.0)
	3	15 (4.0)	13 (3.0)	10 (3.0)	8 (2.0)

	4	8 (2.0)	7 (2.0)	6 (2.0)	7 (2.0)
	Unknown/not assessed	0	0	0	0
JP (n=295)	0	160 (54.0)	155 (53.0)	148 (50.0)	150 (51.0)
	1	103 (35.0)	115 (39.0)	112 (38.0)	116 (39.0)
	2	18 (6.0)	17 (6.0)	26 (9.0)	18 (6.0)
	3	8 (3.0)	4 (1.0)	6 (2.0)	7 (2.0)
	4	4 (1.0)	4 (1.0)	3 (1.0)	4 (1.0)
	Unknown/not assessed	0	0	0	0

All data are presented as n (%).

^aIncludes the UK, IT, FR, ES, and DE.

Adv. Dx advanced diagnosis, *BR* Brazil, *DE* Germany, *ES* Spain, *EU5* 5 countries from the European Union, *FR* France, *IT* Italy, *JP* Japan, *Tx* treatment, *TW* Taiwan, *UK* United Kingdom, *US* United States

Supplementary Table S4. Patients with Primary and Secondary Metastatic Sites – Overall and By Country

Country	Metastasis		
	Site	Primary (%)	Secondary (%)
Overall		n=2396	n=2415
	Adrenal glands	297 (12.0)	334 (14.0)
	Bone	742 (31.0)	749 (31.0)
	Brain	256 (11.0)	317 (13.0)
	CNS	74 (3.0)	100 (4.0)
	Contralateral lung	1157 (48.0)	907 (38.0)
	Liver	430 (18.0)	457 (19.0)
	Lymph node	688 (29.0)	662 (27.0)
	Pleura	612 (26.0)	563 (23.0)
	Visceral/soft tissue	93 (4.0)	81 (3.0)
	Other/don't know	148 (6.0)	41 (2.0)
	None	0	354 (15.0)
US		n=327	n=326
	Adrenal glands	37 (11.0)	35 (11.0)
	Bone	76 (23.0)	59 (18.0)
	Brain	32 (10.0)	31 (10.0)
	CNS	1 (<1.0)	2 (1.0)
	Contralateral lung	146 (45.0)	77 (24.0)
	Liver	57 (17.0)	47 (14.0)
	Lymph node	84 (26.0)	74 (23.0)
	Pleura	57 (17.0)	42 (13.0)
	Visceral/soft tissue	7 (2.0)	6 (2.0)
	Other/don't know	10 (3.0)	6 (2.0)
	None	0	89 (27.0)
BR		n=233	n=242
	Adrenal glands	23 (10.0)	38 (16.0)
	Bone	87 (37.0)	99 (41.0)
	Brain	13 (6.0)	22 (9.0)
	CNS	9 (4.0)	22 (9.0)
	Contralateral lung	114 (49.0)	97 (40.0)
	Liver	38 (16.0)	57 (24.0)
	Lymph node	37 (16.0)	48 (20.0)
	Pleura	62 (27.0)	53 (22.0)
	Visceral/soft tissue	7 (3.0)	11 (5.0)
	Other/don't know	12 (5.0)	4 (2.0)
	None	0	13 (5.0)
UK		n=269	n=274
	Adrenal glands	38 (14.0)	59 (22.0)
	Bone	69 (26.0)	97 (35.0)
	Brain	19 (7.0)	32 (12.0)
	CNS	3 (1.0)	8 (3.0)
	Contralateral lung	139 (52.0)	103 (38.0)
	Liver	47 (18.0)	73 (27.0)
	Lymph node	71 (26.0)	72 (26.0)

IT	Pleura	54 (20.0)	59 (22.0)
	Visceral/soft tissue	17 (6.0)	15 (6.0)
	Other/don't know	12 (5.0)	3 (1.0)
	None	0	18 (7.0)
		n=246	n=247
	Adrenal glands	50 (20.0)	64 (26.0)
	Bone	93 (38.0)	93 (38.0)
	Brain	30 (12.0)	27 (11.0)
	CNS	17 (7.0)	19 (8.0)
	Contralateral lung	116 (47.0)	102 (41.0)
	Liver	54 (22.0)	75 (30.0)
	Lymph node	93 (38.0)	100 (41.0)
FR	Pleura	81 (33.0)	78 (32.0)
	Visceral/soft tissue	12 (5.0)	10 (4.0)
	Other/don't know	8 (3.0)	2 (1.0)
	None	0	11 (5.0)
		n=257	n=257
	Adrenal glands	52 (20.0)	49 (19.0)
	Bone	90 (35.0)	83 (32.0)
	Brain	46 (18.0)	46 (18.0)
	CNS	8 (3.0)	9 (4.0)
	Contralateral lung	105 (41.0)	97 (38.0)
	Liver	74 (29.0)	77 (30.0)
	Lymph node	81 (32.0)	77 (30.0)
ES	Pleura	71 (28.0)	64 (25.0)
	Visceral/soft tissue	8 (3.0)	12 (5.0)
	Other/don't know	8 (3.0)	3 (1.0)
	None	0	19 (7.0)
		n=295	n=295
	Adrenal glands	50 (17.0)	36 (12.0)
	Bone	119 (40.0)	100 (34.0)
	Brain	19 (6.0)	17 (6.0)
	CNS	26 (9.0)	26 (9.0)
	Contralateral lung	179 (61.0)	144 (49.0)
	Liver	69 (23.0)	55 (19.0)
	Lymph node	87 (30.0)	94 (32.0)
DE	Pleura	83 (28.0)	82 (28.0)
	Visceral/soft tissue	14 (5.0)	9 (3.0)
	Other/don't know	2 (1.0)	2 (1.0)
	None	0	34 (12.0)
		n=171	n=172
	Adrenal glands	23 (14.0)	14 (8.0)
	Bone	53 (31.0)	46 (27.0)
	Brain	16 (9.0)	22 (13.0)
	CNS	5 (3.0)	3 (2.0)
	Contralateral lung	83 (49.0)	60 (35.0)
	Liver	50 (29.0)	19 (11.0)
	Lymph node	63 (37.0)	44 (26.0)

TW	Pleura	42 (25.0)	41 (24.0)
	Visceral/soft tissue	7 (4.0)	12 (7.0)
	Other/don't know	2 (1.0)	1 (1.0)
	None	0	50 (29.0)
		n=346	n=338
	Adrenal glands	19 (6.0)	15 (4.0)
	Bone	133 (38.0)	85 (25.0)
	Brain	68 (20.0)	57 (17.0)
	CNS	4 (1.0)	5 (2.0)
	Contralateral lung	175 (51.0)	126 (37.0)
	Liver	27 (8.0)	22 (7.0)
	Lymph node	133 (38.0)	81 (24.0)
	Pleura	140 (41.0)	78 (23.0)
JP	Visceral/soft tissue	6 (2.0)	4 (1.0)
	Other/don't know	4 (1.0)	12 (4.0)
	None	0	119 (35.0)
		n=252	n=264
	Adrenal glands	5 (2.0)	24 (9.0)
	Bone	22 (9.0)	87 (33.0)
	Brain	13 (5.0)	63 (24.0)
	CNS	1 (<1.0)	6 (2.0)
	Contralateral lung	100 (40.0)	101 (38.0)
	Liver	14 (6.0)	32 (12.0)
	Lymph node	39 (16.0)	72 (27.0)
	Pleura	22 (9.0)	66 (25.0)
	Visceral/soft tissue	15 (6.0)	2 (1.0)
EU5 ^a	Other/don't know	90 (36.0)	8 (3.0)
	None	0	1 (<1.0)
		n=1238	n=1245
	Adrenal glands	213 (17.0)	222 (18.0)
	Bone	424 (34.0)	419 (34.0)
	Brain	130 (11.0)	144 (12.0)
	CNS	59 (5.0)	65 (5.0)
	Contralateral lung	622 (50.0)	506 (41.0)
	Liver	294 (24.0)	299 (24.0)
	Lymph node	395 (32.0)	387 (31.0)
	Pleura	331 (27.0)	324 (26.0)
	Visceral/soft tissue	58 (5.0)	58 (5.0)
	Other/don't know	32 (3.0)	11 (1.0)
	None	0	132 (11.0)

All data are presented as n (%).

^aIncludes the UK, IT, FR, ES, and DE.

BR Brazil, CNS central nervous system, DE Germany, ES Spain, EU5 5 countries from the European Union, FR France, IT Italy, JP Japan, TW Taiwan; UK United Kingdom, US United States

Supplementary Table S5. Annual Household Income Across Countries

Income in Respective Currency	Patients, n (%)
	USA, n=160
≤\$5,000	0
\$5,001 - \$15,000	3 (2.0)
\$15,001 - \$25,000	10 (6.0)
\$25,001 - \$50,000	27 (17.0)
\$50,001 - \$75,000	36 (23.0)
\$75,001 - \$100,000	18 (11.0)
\$100,001 - \$125,000	10 (6.0)
\$125,001 - \$150,000	4 (3.0)
\$150,001 - \$175,000	10 (6.0)
\$175,001 - \$200,000	2 (1.0)
>\$200,000	3 (2.0)
I prefer not to answer	34 (21.0)
Ns	3 (2.0)
	BR, n=128
≤R\$640	2 (2.0)
R\$641 - R\$1,500	0
R\$1,501 - R\$2,410	5 (14.0)
R\$2,411 - R\$4,450	14 (11.0)
R\$4,451 - R\$8,700	16 (13.0)
R\$8,701 - R\$15,000	20 (16.0)
>R\$15,001	27 (21.0)
I prefer not to answer	44 (34.0)
Ns	0
	UK, n=39
≤£10,000	0
£10,001 - £20,000	5 (9.0)
£20,001 - £30,000	6 (11.0)
£30,001 - £40,000	9 (16.0)
£40,001 - £50,000	7 (13.0)
£50,001 - £60,000	7 (13.0)
£60,001 - £70,000	2 (4.0)
£70,001 - £80,000	3 (5.0)
£80,001 - £90,000	0
>£90,000	0
I prefer not to answer	16 (29.0)
Ns	0
	IT, n=79
≤€10,000	1 (1.0)
€10,001 - €20,000	13 (16.0)
€20,001 - €30,000	17 (22.0)
€30,001 - €40,000	17 (22.0)
€40,001 - €50,000	6 (8.0)
€50,001 - €60,000	4 (5.0)
€60,001 - €70,000	1 (1.0)
€70,001 - €80,000	0
€80,001 - €90,000	0
>€90,000	0

I prefer not to answer	20 (25.0)
Ns	0
FR, n=79	
≤€10,000	4 (5.0)
€10,001 - €20,000	14 (18.0)
€20,001 - €30,000	11 (14.0)
€30,001 - €40,000	11 (14.0)
€40,001 - €50,000	12 (15.0)
€50,001 - €60,000	3 (4.0))
€60,001 - €70,000	1 (1.0)
€70,001 - €80,000	0
€80,001 - €90,000	1 (1.0)
>€90,000	0
I prefer not to answer	17 (22.0)
Ns	5 (6.0)
ES, n=127	
≤€10,000	6 (5.0)
€10,001 - €20,000	11 (9.0)
€20,001 - €30,000	18 (14.0)
€30,001 - €40,000	30 (24.0)
€40,001 - €50,000	14 (11.0)
€50,001 - €60,000	2 (2.0)
€60,001 - €70,000	5 (4.0)
€70,001 - €80,000	4 (3.0)
€80,001 - €90,000	1 (1.0)
>€90,000	0
I prefer not to answer	28 (22.0)
Ns	8 (6.0)
DE, n=151	
≤€10,000	2 (1.0)
€10,001 - €20,000	18 (12.0)
€20,001 - €30,000	31 (21.0)
€30,001 - €40,000	13 (9.0)
€40,001 - €50,000	4 (3.0)
€50,001 - €60,000	3 (2.0)
€60,001 - €70,000	5 (3.0)
€70,001 - €80,000	7 (5.0)
€80,001 - €90,000	8 (5.0)
>€90,000	1 (1.0)
I prefer not to answer	51 (34.0)
Ns	8 (5.0)
EU^a, n=436	
≤€10,000	13 (3.0)
€10,001 - €20,000	56 (13.0)
€20,001 - €30,000	77 (18.0)
€30,001 - €40,000	71 (16.0)
€40,001 - €50,000	36 (8.0)
€50,001 - €60,000	12 (3.0)
€60,001 - €70,000	12 (3.0)
€70,001 - €80,000	11 (3.0)

€80,001 - €90,000	10 (2.0)
>€90,000	1 (<1)
I prefer not to answer	116 (27.0)
Ns	21 (5.0)
TW, n=49	
≤NT\$300,000	11 (22.0)
NT\$300,001 - 400,000	9 (18.0)
NT\$400,001 - 500,000	6 (12.0)
NT\$500,001 - 600,000	1 (2.0)
NT\$600,001 - 700,000	3 (6.0)
NT\$700,001 - 800,000	1 (2.0)
NT\$800,001 - 1,000,000	1 (2.0)
NT\$1,000,001 - 1,200,000	1 (2.0)
NT\$1,200,001 - 1,400,000	3 (6.0)
>NT\$1,400,000	4 (8.0)
I prefer not to answer	9 (18.0)
Ns	0
JP, n=134	
≤¥1,000,000	13 (10.0)
¥1,000,000 - ¥2,000,000	20 (15.0)
¥2,000,000 - ¥3,000,000	17 (13.0)
¥3,000,000 - ¥4,000,000	15 (11.0)
¥4,000,000 - ¥5,000,000	9 (7.0)
¥5,000,000 - ¥6,000,000	10 (7.0)
¥6,000,000 - ¥7,000,000	8 (6.0)
¥7,000,000 - ¥8,000,000	6 (4.0)
>¥8,000,000	8 (6.0)
I prefer not to answer	24 (18.0)
Ns	4 (3.0)

All data are presented as n (%).

^aIncludes IT, FR, ES, and DE. \$ US dollar, R\$ Brazilian Real, £ pound, €, euro, NT\$, Taiwan dollar, ¥, yen, BR Brazil, DE Germany, ES Spain, EU European Union, FR France, IT Italy, JP Japan, Ns Not stated, TW Taiwan, UK United Kingdom, US United States

Supplementary Table S6. Treatment Combinations – Overall and By Country

Country	Therapy	Line of Therapy		
		1L	2L	3L
Overall (N=2857)		n=2857	n=493	n=84
	BSC Only	38 (1.0)	6 (1.0)	1 (1.0)
	Chemotherapy	150 (5.0)	77 (16.0)	16 (19.0)
	Chemotherapy+Immunotherapy	20 (1.0)	12 (2.0)	2 (2.0)
	Chemotherapy+Other	18 (1.0)	1 (<1.0)	1 (1.0)
	Chemotherapy+Targeted	101 (4.0)	34 (7.0)	7 (8.0)
	Chemotherapy+Targeted+Immunotherapy	21 (1.0)	12 (2.0)	3 (4.0)
	Immunotherapy	26 (1.0)	26 (5.0)	8 (10.0)
	Other	17 (1.0)	4 (1.0)	0
	Targeted	2451 (86.0)	316 (64.0)	44 (52.0)
	Targeted+Immunotherapy	7 (<1.0)	4 (1.0)	1 (1.0)
	Targeted+Other	6 (<1.0)	1 (<1.0)	1 (1.0)
	Chemotherapy+Targeted+Other	1 (<1.0)	0	0
	Immunotherapy+Other	1 (<1.0)	0	0
US (n=422)		n=422	n=41	n=7
	BSC Only	0	1 (2.0)	0
	Chemotherapy	20 (5.0)	1 (2.0)	0
	Chemotherapy+Immunotherapy	8 (2.0)	1 (2.0)	0
	Chemotherapy+Other	1 (<1.0)	1 (2.0)	0
	Chemotherapy+Targeted	14 (3.0)	4 (10.0)	0
	Chemotherapy+Targeted+Immunotherapy	4 (1.0)	1 (2.0)	0
	Immunotherapy	2 (<1.0)	2 (5.0)	2 (29.0)
	Other	13 (3.0)	1 (2.0)	0
	Targeted	358 (85.0)	29 (71.0)	5 (71.0)
	Targeted+Immunotherapy	1 (<1.0)	0	0
	Targeted+Other	1 (<1.0)	0	0
	Chemotherapy+Targeted+Other	0	0	0
	Immunotherapy+Other	0	0	0
BR (n=313)		n=313	n=35	n=5
	BSC Only	30 (10.0)	3 (9.0)	0

	Chemotherapy	32 (10.0)	3 (9.0)	0
	Chemotherapy+Immunotherapy	7 (2.0)	2 (6.0)	0
	Chemotherapy+Other	2 (1.0)	0	0
	Chemotherapy+Targeted	25 (8.0)	1 (3.0)	2 (40.0)
	Chemotherapy+Targeted+Immunotherapy	13 (4.0)	0	0
	Immunotherapy	10 (3.0)	5 (14.0)	0
	Other	0	0	0
	Targeted	193 (62.0)	21 (60.0)	3 (60.0)
	Targeted+Immunotherapy	1 (<1.0)	0	0
	Targeted+Other	0	0	0
	Chemotherapy+Targeted+Other	0	0	0
	Immunotherapy+Other	0	0	0
UK (n=279)		n=279	n=53	n=1
	BSC Only	0	0	0
	Chemotherapy	4 (1.0)	3 (6.0)	0
	Chemotherapy+Immunotherapy	0	0	0
	Chemotherapy+Other	1 (<1.0)	0	0
	Chemotherapy+Targeted	0	1 (2.0)	0
	Chemotherapy+Targeted+Immunotherapy	0	5 (9.0)	0
	Immunotherapy	0	3 (6.0)	0
	Other	1 (<1.0)	0	0
	Targeted	273 (98.0)	41 (77.0)	1 (100.0)
	Targeted+Immunotherapy	0	0	0
	Targeted+Other	0	0	0
	Chemotherapy+Targeted+Other	0	0	0
	Immunotherapy+Other	0	0	0
IT (n=287)		n=287	n=53	n=2
	BSC Only	3 (1.0)	0	0
	Chemotherapy	14 (5.0)	12 (23.0)	1 (50.0)
	Chemotherapy+Immunotherapy	2 (1.0)	1 (2.0)	0
	Chemotherapy+Other	2 (1.0)	0	0
	Chemotherapy+Targeted	0	0	0
	Chemotherapy+Targeted+Immunotherapy	0	0	0

	Immunotherapy	4 (1.0)	2 (4.0)	1 (50.0)
	Other	0	0	0
	Targeted	260 (91.0)	36 (68.0)	0
	Targeted+Immunotherapy	0	1 (2.0)	0
	Targeted+Other	2 (1.0)	1 (2.0)	0
	Chemotherapy+Targeted+Other	0	0	0
	Immunotherapy+Other	0	0	0
FR (n=285)		n=285	n=50	n=3
	BSC Only	2 (1.0)	0	1 (33.0)
	Chemotherapy	11 (4.0)	5 (10.0)	0
	Chemotherapy+Immunotherapy	0	1 (2.0)	0
	Chemotherapy+Other	1 (<1.0)	0	0
	Chemotherapy+Targeted	5 (2.0)	2 (4.0)	0
	Chemotherapy+Targeted+Immunotherapy	0	0	0
	Immunotherapy	2 (1.0)	3 (6.0)	1 (33.0)
	Other	0	0	0
	Targeted	262 (92.0)	39 (78.0)	1 (33.0)
	Targeted+Immunotherapy	0	0	0
	Targeted+Other	1 (<1.0)	0	0
	Chemotherapy+Targeted+Other	1 (<1.0)	0	0
	Immunotherapy+Other	0	0	0
ES (n=302)		n=302	n=36	n=1
	BSC Only	1 (<1.0)	0	0
	Chemotherapy	1 (0.0)	5 (14.0)	0
	Chemotherapy+Immunotherapy	3 (1.0)	0	0
	Chemotherapy+Other	0	0	0
	Chemotherapy+Targeted	0	0	0
	Chemotherapy+Targeted+Immunotherapy	6 (2.0)	0	0
	Immunotherapy	0	2 (6.0)	0
	Other	1 (<1.0)	0	0
	Targeted	3 (1.0)	29 (81.0)	1 (100.0)
	Targeted+Immunotherapy	286 (95.0)	0	0
	Targeted+Other	1 (<1.0)	0	0
	Chemotherapy+Targeted+Other	1 (<1.0)	0	0

	Immunotherapy+Other	0	0	0
DE (n=284)		n=284	n=67	n=5
	BSC Only	1 (<1.0)	0	0
	Chemotherapy	32 (11.0)	2 (3.0)	0
	Chemotherapy+Immunotherapy	3 (1.0)	0	0
	Chemotherapy+Other	11 (4.0)	0	0
	Chemotherapy+Targeted	39 (14.0)	6 (9.0)	0
	Chemotherapy+Targeted+Immunotherapy	3 (1.0)	3 (4.0)	0
	Immunotherapy	5 (2.0)	4 (6.0)	1 (20.0)
	Other	0	1 (1.0)	0
	Targeted	187 (66.0)	48 (72.0)	3 (60.0)
	Targeted+Immunotherapy	3 (1.0)	3 (4.0)	1 (20.0)
	Targeted+Other	0	0	0
	Chemotherapy+Targeted+Other	0	0	0
	Immunotherapy+Other	0	0	0
EU5^a (n=1437)		n=1437	n=259	n=12
	BSC Only	7 (1.0)	0	1 (8.0)
	Chemotherapy	64 (4.0)	27 (10.0)	1 (8.0)
	Chemotherapy+Immunotherapy	5 (<1.0)	2 (1.0)	0
	Chemotherapy+Other	15 (1.0)	0	0
	Chemotherapy+Targeted	50 (3.0)	9 (4.0)	0
	Chemotherapy+Targeted+Immunotherapy	3 (<1.0)	8 (3.0)	0
	Immunotherapy	12 (1.0)	14 (5.0)	3 (25.0)
	Other	4 (<1.0)	1 (<1.0)	0
	Targeted	1268 (88.0)	193 (75.0)	6 (50.0)
	Targeted+Immunotherapy	4 (<1.0)	4 (2.0)	1 (8.0)
	Targeted+Other	4 (<1.0)	1 (<1.0)	0
	Chemotherapy+Targeted+Other	1 (<1.0)	0	0
	Immunotherapy+Other	0	0	0
TW (n=390)		n=390	n=80	n=26
	BSC Only	1 (<1.0)	2 (3.0)	0
	Chemotherapy	6 (2.0)	31 (39.0)	7 (27.0)

	Chemotherapy+Immunotherapy	0	3 (4.0)	1 (4.0)
	Chemotherapy+Other	0	0	0
	Chemotherapy+Targeted	7 (2.0)	8 (10.0)	1 (4.0)
	Chemotherapy+Targeted+Immunotherapy	0	2 (3.0)	1 (4.0)
	Immunotherapy	0	0	0
	Other	0	2 (3.0)	0
	Targeted	374 (96.0)	32 (40.0)	15 (58.0)
	Targeted+Immunotherapy	1 (<1.0)	0	0
	Targeted+Other	0	0	1 (4.0)
	Chemotherapy+Targeted+Other	0	0	0
	Immunotherapy+Other	1 (<1.0)	0	0
JP (n=295)		n=295	n=78	n=34
	BSC Only	0	0	0
	Chemotherapy	28 (9.0)	15 (19.0)	8 (24.0)
	Chemotherapy+Immunotherapy	0	4 (5.0)	1 (3.0)
	Chemotherapy+Other	0	0	1 (3.0)
	Chemotherapy+Targeted	5 (2.0)	12 (15.0)	4 (12.0)
	Chemotherapy+Targeted+Immunotherapy	1 (<1.0)	1 (1.0)	2 (6.0)
	Immunotherapy	2 (1.0)	5 (6.0)	3 (9.0)
	Other	0	0	0
	Targeted	258 (87.0)	41 (53.0)	15 (44.0)
	Targeted+Immunotherapy	0	0	0
	Targeted+Other	1 (<1.0)	0	0
	Chemotherapy+Targeted+Other	0	0	0
	Immunotherapy+Other	0	0	0

All data are presented as %.

^aIncludes the UK, IT, FR, ES, and DE.

1L first line, 2L second line, 3L third line, BSC, best supportive care, BR Brazil, DE Germany, ES Spain, EU5 5 countries from the European Union, FR France, IT Italy, JP Japan, TW Taiwan, UK United Kingdom, US United States

Supplementary Table S7. Clinical Effectiveness – Median TTNT, TTF, and Response to Treatment

	Overall (n=2857)	US (n=422)	BR (n=313)	UK (n=279)	IT (n=287)	FR (n=285)	ES (n=302)	DE (n=284)	EU5 ^a (n=1437)	TW (n=390)	JP (n=295)
TTNT in Months, median (IQR)											
1L to 2L	n=441 14.0 (8.0-22.0)	n=31 16.0 (10.0-23.0)	n=32 16.5 (7.0-27.5)	n=47 16.0 (10.0-21.0)	n=38 14.0 (10.0-17.3)	n=46 16.0 (9.0-25.3)	n=35 14.0 (6.0-21.0)	n=62 9.0 (4.0-18.0)	n=228 14.0 (8.0-21.0)	n=78 14.0 (9.0-23.0)	n=72 13.5 (8.0-20.8)
2L to 3L	n=76 11.0 (6.0-19.8)	n=5 12.0 (9.5-21.0)	n=4 22.0 (17.0-31.5)	n=1 18.0 (18.0-18.0)	n=2 12.0 (11.0-13.0)	n=3 10.0 (3.0-10.0)	n=1 6.0 (6.0-6.0)	n=5 10.0 (4.0-17.0)	n=12 10.0 (5.3-13.8)	n=26 10.5 (6.0-17.5)	n=29 11.0 (6.5-25.5)
TTF in months, median (IQR)	n=460 13.3 (7.9-20.9)	n=38 13.4 (6.9-20.8)	n=37 13.0 (5.5-25.7)	n=48 15.2 (9.8-21.8)	n=39 13.0 (9.7-18.0)	n=46 15.2 (9.1-25.3)	n=35 14.0 (5.8-20.0)	n=63 8.0 (4.2-16.6)	n=231 13.4 (8.0-20.7)	n=80 13.1 (8.6-22.1)	n=74 13.3 (7.9-20.2)
FR, n (%)											
1L	n=311 38 (12.0)	n=27 5 (19.0)	n=22 2 (9.0)	n=23 2 (9.0)	n=22 1 (5.0)	n=35 4 (11.0)	n=20 0	n=43 17 (40.0)	n=143 24 (17.0)	n=73 5 (7.0)	n=46 2 (4.0)
2L	n=57 2 (4.0)	n=3 0	n=4 0	n=2 0	n=2 0	n=1 0	n=0 0	n=1 0	n=6 0	n=21 1 (5.0)	n=23 1 (4.0)
PR, n (%)											
1L	n=311 258 (83.0)	n=27 22 (82.0)	n=22 16 (73.0)	n=23 21 (91.0)	n=22 19 (86.0)	n=35 29 (83.0)	n=20 19 (95.0)	n=43 25 (58.0)	n=143 113 (79.0)	n=73 63 (86.0)	n=46 44 (96.0)
2L	n=57 45 (79.0)	n=3 3 (100.0)	n=4 3 (75.0)	n=2 2 (100.0)	n=2 2 (100.0)	n=1 0	n=0 0	n=1 1 (100.0)	n=6 5 (83.0)	n=21 15 (71.0)	n=23 19 (83.0)
No Response, n (%)											
1L	n=311 15 (5.0)	n=27 0	n=22 4 (18.0)	n=23 0	n=22 2 (9.0)	n=35 2 (6.0)	n=20 1 (5.0)	n=43 1 (2.0)	n=143 6 (4.0)	n=73 5 (7.0)	n=46 0
2L	n=57 10 (18.0)	n=3 0	n=4 1 (25.0)	n=2 0	n=2 0	n=1 1 (100.0)	n=0 0	n=1 0	n=6 1 (17.0)	n=21 5 (24.0)	n=23 3 (13.0)
Reason for discontinuation, n (%)											
1L	n=223	n=24	n=14	n=30	n=31	n=15	n=18	n=43	n=137	n=11	n=37
No Response	26 (12.0)	8 (33.0)	3 (21.0)	2 (7.0)	5 (16.0)	1 (7.0)	1 (6.0)	5 (12.0)	14 (10.0)	0	1 (3.0)
Progression	172 (77.0)	17 (71.0)	11 (79.0)	27 (90.0)	26 (84.0)	14 (93.0)	16 (89.0)	27 (63.0)	107 (78.0)	9 (82.0)	25 (68.0)
Patient Request	8 (4.0)	0	1 (7.0)	0	3 (10.0)	0	2 (11.0)	1 (2.0)	6 (4.0)	0	1 (3.0)
Side-effects	44 (20.0)	4 (17.0)	3 (21.0)	1 (3.0)	11 (36.0)	0	1 (6.0)	12 (28.0)	25 (18.0)	2 (18.0)	10 (27.0)

Treatment											
Cost to Patient	1 (<1.0)	0	0	0	0	0	0	0	0	0	0
Other	3 (1.0)	1 (4.0)	0	0	2 (7.0)	0	0	0	2 (2.0)	0	1 (3.0)
2L	n=29	n=4	n=2	n=0	n=0	n=2	n=1	n=4	n=7	n=5	n=11
No Response	2 (7.0)	0	1 (50.0)	0	0	0	0	1 (25.0)	1 (14.0)	0	0
Progression	24 (83.0)	3 (75.0)	1 (50.0)	0	0	2 (100.0)	1 (100.0)	4 (100.0)	7 (100.0)	5 (100.0)	8 (73.07)
Side-effects	5 (17.0)	2 (50.0)	0	0	0	0	0	0	0	0	3 (27.0)

^aIncludes the UK, IT, FR, ES, and DE.

BR Brazil, *DE* Germany, *FR* full response, *ES* Spain, *EUS* 5 countries from the European Union, *FR* France, *IT* Italy, *IQR* interquartile range, *JP* Japan, *PR* partial response, TTNT, time to next treatment, TTF, time to treatment failure, *TW* Taiwan, *UK* United Kingdom, *US* United States

Supplementary Table S8. Top AEs by Severity – Overall Population and By Country

Country	Grade	Side Effect												
		Fatigue	Nausea	Diarrhea	Rash	Loss of Appetite	Dry Skin	Anemia	Weight Loss	Headache	Vision Change	Hair Loss	Nail Problems	Mouth sore
Overall		n=204	n=178	n=333	n=334	n=191	n=235	n=76	n=93	n=58	n=15	n=66	n=104	n=51
	1	111 (54.0)	111 (62.0)	205 (62.0)	179 (54.0)	107 (56.0)	154 (66.0)	56 (74.0)	59 (63.0)	37 (64.0)	5 (33.0)	36 (55.0)	54 (52.0)	36 (71.0)
	2	71 (35.0)	51 (29.0)	111 (33.0)	126 (38.0)	73 (38.0)	66 (28.0)	14 (18.0)	24 (26.0)	16 (28.0)	7 (47.0)	17 (26.0)	37 (36.0)	12 (24.0)
	3	22 (11.0)	13 (7.0)	14 (4.0)	28 (8.0)	11 (6.0)	15 (6.0)	5 (7.0)	10 (11.0)	3 (5.0)	3 (20.0)	11 (17.0)	12 (12.0)	3 (6.0)
	4	0	3 (2.0)	2 (1.0)	1 (<1.0)	0	0	1 (1.0)	0	1 (2.0)	0	2 (3.0)	1 (1.0)	0
	Don't know	0	0	1 (<1.0)	0	0	0	0	0	1 (2.0)	0	0	0	0
US		n=42	n=41	n=36	n=34	n=28	n=19	n=15	n=13	n=11	n=8	n=7	n=1	n=3
	1	18 (43.0)	23 (56.0)	25 (69.0)	18 (53.0)	16 (57.0)	9 (47.0)	5 (33.0)	9 (69.0)	3 (27.0)	0	6 (86.0)	0	1 (33.0)
	2	18 (43.0)	16 (39.0)	11 (31.0)	13 (38.0)	11 (39.0)	9 (47.0)	7 (47.0)	2 (15.0)	7 (64.0)	5 (63.0)	0	1 (100.0)	1 (33.0)
	3	6 (14.0)	2 (5.0)	0	3 (9.0)	1 (4.0)	1 (5.0)	2 (13.0)	2 (15.0)	1 (9.0)	3 (38.0)	1 (14.0)	0	1 (33.0)
	4	0	0	0	0	0	0	1 (7.0)	0	0	0	0	0	0
	Don't know	0	0	0	0	0	0	0	0	0	0	0	0	0
BR		n=18	n=16	n=25	n=23	n=13	n=23	n=8	n=6	n=5	n=0	n=5	n=4	n=2
	1	10 (56.0)	13 (81.0)	19 (76.0)	11 (48.0)	8 (62.0)	14 (61.0)	8 (100.0)	3 (50.0)	3 (60.0)	0	3 (60.0)	1 (25.0)	2 (100.0)
	2	6 (33.0)	2 (13.0)	3 (12.0)	6 (26.0)	3 (23.0)	4 (17.0)	0	2 (33.0)	2 (40.0)	0	2 (40.0)	1 (25.0)	0
	3	2 (11.0)	1 (6.0)	3 (12.0)	6 (26.0)	2 (15.0)	5 (22.0)	0	1 (17.0)	0	0	0	2 (50.0)	0
	4	0	0	0	0	0	0	0	0	0	0	0	0	0
	Don't know	0	0	0	0	0	0	0	0	0	0	0	0	0
UK		n=21	n=13	n=36	n=38	n=9	n=19	n=2	n=2	n=3	n=1	n=5	n=9	n=5
	1	13 (62.0)	12 (92.0)	25 (69.0)	26 (69.0)	7 (78.0)	12 (63.0)	2 (100.0)	2 (100.0)	3 (100.0)	1 (100.0)	2 (40.0)	7 (78.0)	5 (100.0)
	2	7 (33.0)	1 (8.0)	10 (28.0)	11 (29.0)	2 (22.0)	7 (37.0)	0	0	0	0	1 (20.0)	2 (22.0)	0
	3	1 (5.0)	0	1 (3.0)	1 (3.0)	0	0	0	0	0	0	1 (20.0)	0	0
	4	0	0	0	0	0	0	0	0	0	0	1 (20.0)	0	0
	Don't know	0	0	0	0	0	0	0	0	0	0	0	0	0
IT		n=16	n=30	n=39	n=24	n=17	n=24	n=13	n=9	n=11	n=0	n=12	n=5	n=8
	1	11 (69.0)	14 (47.0)	21 (54.0)	10 (42.0)	7 (41.0)	14 (58.0)	8 (62.0)	6 (67.0)	6 (55.0)	0	6 (50.0)	5 (100.0)	5 (63.0)
	2	3 (19.0)	5 (17.0)	12 (31.0)	12 (50.0)	6 (35.0)	7 (29.0)	2 (15.0)	2 (22.0)	1 (9.0)	0	3 (25.0)	0	2 (25.0)
	3	2 (13.0)	8 (27.0)	3 (8.0)	2 (8.0)	4 (24.0)	3 (13.0)	3 (23.0)	1 (11.0)	2 (18.0)	0	2 (17.0)	0	1 (13.0)
	4	0	3 (10.0)	2 (5.0)	0	0	0	0	0	1 (9.0)	0	1 (8.0)	0	0
	Don't know	0	0	1 (3.0)	0	0	0	0	0	1 (9.0)	0	0	0	0
FR		n=16	n=9	n=21	n=13	n=11	n=12	n=5	n=6	n=2	n=0	n=2	n=0	n=4
	1	7 (44.0)	6 (67.0)	11 (52.0)	9 (69.0)	6 (55.0)	8 (67.0)	4 (80.0)	1 (17.0)	1 (50.0)	0	2 (100.0)	0	2 (50.0)
	2	4 (25.0)	2 (22.0)	9 (43.0)	4 (31.0)	3 (27.0)	4 (33.0)	1 (20.0)	3 (50.0)	1 (50.0)	0	0	0	2 (50.0)
	3	5 (31.0)	1 (11.0)	1 (5.0)	0	2 (18.0)	0	0	2 (33.0)	0	0	0	0	0

	4	0	0	0	0	0	0	0	0	0	0	0	0	0
	Don't know	0	0	0	0	0	0	0	0	0	0	0	0	0
ES		n=18	n=10	n=35	n=16	n=15	n=28	n=15	n=5	n=7	n=1	n=7	n=3	n=1
	1	11 (61.0)	8 (80.0)	26 (74.0)	13 (81.0)	10 (67.0)	24 (86.0)	13 (87.0)	4 (80.0)	6 (86.0)	0	0	3 (100.0)	1 (100.0)
	2	7 (39.0)	2 (20.0)	9 (26.0)	3 (19.0)	4 (27.0)	4 (14.0)	2 (13.0)	0	1 (14.0)	1 (100.0)	2 (29.0)	0	0
	3	0	0	0	0	1 (7.0)	0	0	1 (20.0)	0	0	5 (71.0)	0	0
	4	0	0	0	0	0	0	0	0	0	0	0	0	0
	Don't know	0	0	0	0	0	0	0	0	0	0	0	0	0
DE		n=40	n=30	n=36	n=16	n=47	n=22	n=4	n=29	n=8	n=1	n=9	n=1	n=0
	1	17 (43.0)	12 (40.0)	15 (42.0)	13 (81.0)	19 (40.0)	15 (68.0)	4 (100.0)	16 (55.0)	5 (63.0)	0	2 (22.0)	1 (100.0)	0
	2	18 (45.0)	17 (57.0)	20 (56.0)	3 (19.0)	28 (60.0)	7 (32.0)	0	12 (41.0)	3 (38.0)	1 (100.0)	6 (67.0)	0	0
	3	5 (13.0)	1 (3.0)	1 (3.0)	0	0	0	0	1 (3.0)	0	0	1 (11.0)	0	0
	4	0	0	0	0	0	0	0	0	0	0	0	0	0
	Don't know	0	0	0	0	0	0	0	0	0	0	0	0	0
EU5 ^a		n=111	n=92	n=167	n=107	n=99	n=105	n=39	n=51	n=31	n=3	n=35	n=18	n=18
	1	59 (53.0)	52 (57.0)	98 (59.0)	71 (66.0)	49 (50.0)	73 (70.0)	31 (80.0)	29 (57.0)	21 (68.0)	1 (33.0)	12 (34.0)	16 (89.0)	13 (72.0)
	2	39 (35.0)	27 (29.0)	60 (36.0)	33 (31.0)	43 (44.0)	29 (28.0)	5 (13.0)	17 (33.0)	6 (19.0)	2 (67.0)	12 (34.0)	2 (11.0)	4 (22.0)
	3	13 (12.0)	10 (11.0)	6 (4.0)	3 (3.0)	7 (7.0)	3 (3.0)	3 (8.0)	5 (10.0)	2 (7.0)	0	9 (26.0)	0	1 (6.0)
	4	0	3 (3.0)	2 (1.0)	0	0	0	0	0	1 (3.0)	0	2 (6.0)	0	0
	Don't know	0	0	1 (1.0)	0	0	0	0	0	1 (3.0)	0	0	0	0
TW		n=22	n=17	n=72	n=117	n=32	n=61	n=14	n=15	n=10	n=4	n=16	n=64	n=23
	1	13 (59.0)	15 (88.0)	39 (54.0)	46 (39.0)	22 (69.0)	37 (61.0)	12 (86.0)	10 (67.0)	9 (90.0)	4 (100.0)	14 (88.0)	28 (44.0)	15 (65.0)
	2	8 (36.0)	2 (12.0)	28 (39.0)	55 (47.0)	9 (28.0)	18 (30.0)	2 (14.0)	3 (20.0)	1 (10.0)	0	1 (6.0)	25 (39.0)	7 (30.0)
	3	1 (5.0)	0	5 (7.0)	15 (13.0)	1 (3.0)	6 (10.0)	0	2 (13.0)	0	0	1 (6.0)	10 (16.0)	1 (4.3)
	4	0	0	0	1 (1.0)	0	0	0	0	0	0	0	1 (2.0)	0
	Don't know	0	0	0	0	0	0	0	0	0	0	0	0	0
JP		n=11	n=12	n=33	n=53	n=19	n=27	n=0	n=8	n=1	n=0	n=3	n=17	n=5
	1	11 (100.0)	8 (67.0)	24 (73.0)	33 (62.0)	12 (63.0)	21 (78.0)	0	8 (100.0)	1 (100.0)	0	1 (33.0)	9 (53.0)	5 (100.0)
	2	0	4 (33.0)	9 (27.0)	19 (36.0)	7 (37.0)	6 (22.0)	0	0	0	0	2 (67.0)	8 (47.0)	0
	3	0	0	0	1 (2.0)	0	0	0	0	0	0	0	0	0
	4	0	0	0	0	0	0	0	0	0	0	0	0	0
	Don't know	0	0	0	0	0	0	0	0	0	0	0	0	0

All data are presented as n (%).

^aIncludes the UK, IT, FR, ES, and DE.

AE, adverse event, BR Brazil, DE Germany, ES Spain, EU5 5 countries from the European Union, FR France, IT Italy, JP Japan, TW Taiwan, UK United Kingdom, US United States

Supplementary Table S9. Patients in Each Domain of EQ-5D-5L Score – By Country

	Overall	US	BR	UK	IT	FR	ES	DE	EU5 ^a	TW	JP
<i>Mobility</i>	n=952	n=159	n=128	n=55	n=79	n=79	n=125	n=149	n=487	n=49	n=129
I have no problems in walking about	551 (58.0)	127 (80.0)	51 (40.0)	40 (73.0)	38 (48.0)	38 (48.0)	74 (59.0)	74 (50.0)	264 (54.0)	26 (53.0)	83 (64.0)
I have slight problems in walking about	241 (25.0)	28 (18.0)	31 (24.0)	14 (26.0)	28 (35.0)	29 (37.0)	35 (28.0)	35 (24.0)	141 (29.0)	10 (20.0)	31 (24.0)
I have moderate problems in walking about	120 (13.0)	3 (2.0)	30 (23.0)	1 (2.0)	13 (17.0)	8 (10.0)	14 (11.0)	34 (23.0)	70 (14.0)	9 (18.0)	8 (6.0)
I have severe problems in walking about	35 (4.0)	0	14 (11.0)	0	0	3 (4.0)	2 (2.0)	6 (4.0)	11 (2.0)	4 (8.0)	6 (5.0)
I am unable to in walk about	5 (1.0)	1 (1.0)	2 (2.0)	0	0	1 (1.0)	0	0	1 (<1.0)	0	1 (1.0)
Ns	10 (1.0)	1 (1.0)	0	0	0	0	2 (2.0)	2 (1.0)	4 (1.0)	0	5 (4.0)
<i>Self-care</i>	n=945	n=159	n=124	n=55	n=79	n=79	n=124	n=149	n=486	n=49	n=127
I have no problems washing or dressing myself	616 (65.0)	138 (87.0)	50 (40.0)	42 (76.0)	44 (56.0)	51 (65.0)	77 (62.0)	80 (54.0)	294 (61.0)	33 (67.0)	101 (80.0)
I have slight problems washing or dressing myself	219 (23.0)	18 (11.0)	38 (31.0)	13 (24.0)	22 (28.0)	21 (27.0)	36 (29.0)	45 (30.0)	137 (28.0)	8 (16.0)	18 (14.0)
I have moderate problems washing or dressing myself	79 (8.0)	2 (1.0)	18 (15.0)	0	13 (17.0)	5 (6.0)	8 (7.0)	23 (15.0)	49 (10.0)	5 (10.0)	5 (4.0)
I have severe problems washing or dressing myself	26 (3.0)	0	16 (13.0)	0	0	1 (1.0)	3 (2.0)	1 (1.0)	5 (1.0)	2 (4.0)	3 (2.0)
I am unable to wash or dress myself	5 (1.0)	1 (1.0)	2 (2.0)	0	0	1 (1.0)	0	0	1 (<1.0)	1 (2.0)	0
Ns	17 (2.0)	1 (1.0)	4 (3.0)	0	0	0	3 (2.0)	2 (1.0)	5 (1.0)	0	7 (6.0)

Usual activities											
	n=949	n=159	n=127	n=55	n=79	n=79	n=125	n=149	n=487	n=49	n=127
I have no problems doing my usual activities	424 (45.0)	103 (65.0)	34 (27.0)	37 (67.0)	33 (42.0)	34 (43.0)	59 (47.0)	25 (17.0)	188 (39.0)	26 (53.0)	73 (58.0)
I have slight problems doing my usual activities	315 (33.0)	49 (31.0)	46 (36.0)	17 (31.0)	28 (35.0)	29 (37.0)	47 (38.0)	48 (32.0)	169 (35.0)	14 (29.0)	37 (29.0)
I have moderate problems doing my usual activities	163 (17.0)	6 (4.0)	30 (24.0)	1 (2.0)	14 (18.0)	13 (17.0)	17 (14.0)	65 (44.0)	110 (23.0)	4 (8.0)	13 (10.0)
I have severe problems doing my usual activities	42 (4.0)	1 (1.0)	15 (12.0)	0	4 (5.0)	2 (3.0)	2 (2.0)	11 (7.0)	19 (4.0)	3 (6.0)	4 (3.0)
I am unable to do my usual activities	5 (1.0)	0	2 (2.0)	0	0	1 (1.0)	0	0	1 (<1.0)	2 (4.0)	0
Ns	13 (1.0)	1 (1.0)	1 (1.0)	0	0	0	2 (2.0)	2 (1.0)	4 (1.0)	0	7 (6.0)
Pain/discomfort											
	n=951	n=159	n=128	n=55	n=79	n=78	n=125	n=149	n=486	n=49	n=129
I have no pain or discomfort	321 (34.0)	68 (43.0)	20 (16.0)	35 (64.0)	25 (32.0)	21 (27.0)	44 (35.0)	18 (12.0)	143 (29.0)	18 (37.0)	72 (56.0)
I have slight pain or discomfort	382 (40.0)	69 (43.0)	49 (38.0)	19 (35.0)	33 (42.0)	35 (45.0)	54 (43.0)	59 (40.0)	200 (41.0)	18 (37.0)	46 (36.0)
I have moderate pain or discomfort	204 (22.0)	21 (13.0)	42 (33.0)	1 (2.0)	19 (24.0)	15 (19.0)	22 (18.0)	69 (46.0)	126 (26.0)	6 (12.0)	9 (7.0)
I have severe pain or discomfort	39 (4.0)	1 (1.0)	14 (11.0)	0	2 (3.0)	7 (9.0)	4 (3.0)	3 (2.0)	16 (3.0)	6 (12.0)	2 (2.0)
I have extreme pain or discomfort	5 (1.0)	0	3 (2.0)	0	0	0	1 (1.0)	0	1 (<1.0)	1 (2.0)	0
Ns	11 (1.0)	1 (1.0)	0	0	0	1 (1.0)	2 (2.0)	2 (1.0)	5 (1.0)	0	5 (4.0)
Anxiety/depression											
	n=947	n=158	n=127	n=55	n=78	n=79	n=126	n=148	n=486	n=49	n=127
I am not anxious or depressed	338 (36.0)	70 (44.0)	32 (25.0)	30 (55.0)	18 (23.0)	25 (32.0)	44 (35.0)	42 (28.0)	159 (33.0)	13 (27.0)	64 (50.0)
I am slightly anxious or depressed	383 (40.0)	73 (46.0)	44 (35.0)	19 (35.0)	31 (40.0)	30 (38.0)	50 (40.0)	64 (43.0)	194 (40.0)	27 (55.0)	45 (35.0)

I am moderately anxious or depressed	158 (17.0)	13 (8.0)	27 (21.0)	6 (11.0)	25 (32.0)	15 (19.0)	24 (19.0)	31 (21.0)	101 (21.0)	5 (10.0)	12 (9.0)
I am severely anxious or depressed	64 (7.0)	2 (1.0)	24 (19.0)	0	4 (5.0)	8 (10.0)	8 (6.0)	11 (7.0)	31 (6.0)	1 (2.0)	6 (5.0)
I am extremely anxious or depressed	4 (<1.0)	0	0	0	0	1 (1.0)	0	0	1 (<1.0)	3 (6.0)	0
Ns	15 (2.0)	2 (1.0)	1 (1.0)	0	1 (1.0)	0	1 (1.0)	3 (2.0)	5 (1.0)	0	7 (6.0)

All data are presented as n (%).

^aIncludes the UK, IT, FR, ES, and DE.

aNSCLC advanced non-small cell lung cancer, *BR* Brazil, *DE* Germany, *EGFR* epidermal growth factor receptor, *EQ-5D-5L* European Quality of Life 5 Dimension 5 Level, *ES* Spain, *EU5* 5 countries from the European Union, *FR* France, *IT* Italy, *JP* Japan, *TW* Taiwan, *UK* United Kingdom, *US* United States

Supplementary Table S10. FACT Score by Individual Parameters – Overall Population

	EGFR+ aNSCLC Overall	1L	2L	3L
Social/family well-being subscale, mean (SD)	n=940 18.5 (6.1)	n=771 18.5 (6.1)	n=137 18.5 (6.1)	n=32 18.9 (6.5)
Emotional well-being subscale, mean (SD)	n=946 13.8 (4.6)	n=775 13.8 (4.6)	n=138 13.5 (4.6)	n=33 15.0 (4.5)
Functional well-being subscale, mean (SD)	n=949 13.9 (6.7)	n=778 14.0 (6.8)	n=138 12.9 (6.2)	n=33 16.7 (6.2)
Physical well-being subscale, mean (SD)	n=939 19.7 (5.9)	n=771 20.0 (5.9)	n=137 18.0 (5.5)	n=31 20.1 (5.9)
Lung cancer subscale, mean (SD)	n=950 17.4 (4.7)	n=779 17.5 (4.7)	n=138 16.4 (4.4)	n=33 18.9 (4.7)

1L first-line, 2L, second-line, 3L, third-line, aNSCLC advanced non-small cell lung cancer EQ-5D-5L European Quality of Life 5 Dimension 5 Level, EQ-VAS EuroQoL visual analog scale, FACT-L Functional Assessment of Cancer Therapy–Lung, FACT-G Functional Assessment of Cancer Therapy–General

Supplementary Table S11. Reasons for Hospitalization – Overall and By Country

Country	Reason	1 st Visit	2 nd Visit	3 rd Visit	4 th Visit	5 th Visit
Overall		n=827	n=218	n=88	n=44	n=25
	Biopsy	311 (38.0)	33 (15.0)	12 (14.0)	4 (9.0)	2 (8.0)
	For Surgery (excluding biopsy)	84 (10.0)	15 (7.0)	6 (7.0)	1 (2.0)	0
	Treat complication	193 (23.0)	76 (35.0)	26 (30.0)	14 (32.0)	3 (12.0)
	Treatment-related toxicity	93 (11.0)	43 (20.0)	19 (22.0)	7 (16.0)	3 (12.0)
	Other	141 (17.0)	46 (21.0)	22 (25.0)	16 (36.0)	16 (64.0)
	Don't know	5 (1.0)	5 (2.0)	3 (3.0)	2 (5.0)	1 (4.0)
US		n=74	n=22	n=5	n=1	n=0
	Biopsy	15 (20.0)	1 (5.0)	0	1 (100.0)	0
	For Surgery (excluding biopsy)	7 (9.0)	4 (18.0)	1 (20.0)	0	0
	Treat complication	29 (39.0)	5 (23.0)	1 (20.0)	0	0
	Treatment-related toxicity	7 (9.0)	3 (14.0)	1 (20.0)	0	0
	Other	14 (19.0)	8 (36.0)	2 (40.0)	0	0
	Don't know	2 (3.0)	1 (5.0)	0	0	0
BR		n=110	n=50	n=26	n=13	n=3
	Biopsy	27 (25.0)	6 (12.0)	4 (15.0)	1 (8.0)	0
	For Surgery (excluding biopsy)	4 (4.0)	1 (2.0)	2 (8.0)	1 (8.0)	0
	Treat complication	62 (56.0)	34 (68.0)	16 (62.0)	8 (62.0)	3 (100.0)
	Treatment-related toxicity	10 (9.0)	7 (14.0)	3 (12.0)	2 (15.0)	0
	Other	7 (6.0)	1 (2.0)	0	0	0
	Don't know	0	1 (2.0)	1 (4.0)	1 (8.0)	0
UK		n=36	n=9	n=2	n=1	n=0
	Biopsy	2 (6.0)	1 (11.0)	0	0	0
	For Surgery (excluding biopsy)	4 (11.0)	1 (11.0)	0	0	0
	Treat complication	18 (50.0)	4 (44.0)	1 (50.0)	1 (100.0)	0
	Treatment-related toxicity	0	0	0	0	0
	Other	11 (31.0)	3 (33.0)	1 (50.0)	0	0
	Don't know	1 (3.0)	0	0	0	0
		n=62	n=4	n=2	n=0	n=0

IT	Biopsy	34 (55.0)	0	0	0	0
	For Surgery (excluding biopsy)	4 (6.0)	0	0	0	0
	Treat complication	10 (16.0)	2 (50.0)	1 (50.0)	0	0
	Treatment-related toxicity	2 (3.0)	0	0	0	0
	Other	12 (19.0)	1 (25.0)	0	0	0
	Don't know	0	1 (25.0)	1 (50.0)	0	0
FR		n=79	n=22	n=7	n=3	n=1
	Biopsy	33 (42.0)	4 (18.0)	3 (43.0)	0	0
	For Surgery (excluding biopsy)	6 (8.0)	0	0	0	0
	Treat complication	23 (29.0)	12 (55.0)	1 (14.0)	1 (33.0)	0
	Treatment-related toxicity	1 (1.0)	0	0	0	0
	Other	15 (19.0)	6 (27.0)	3 (43.0)	2 (67.0)	1 (100.0)
ES		n=39	n=9	n=1	n=1	n=1
	Biopsy	18 (46.0)	2 (22.0)	0	0	0
	For Surgery (excluding biopsy)	2 (5.0)	3 (33.0)	0	0	0
	Treat complication	13 (33.0)	3 (33.0)	0	0	0
	Treatment-related toxicity	4 (10.0)	0	0	0	0
	Other	2 (5.0)	0	0	0	0
DE	Don't know	0	1 (11.0)	1 (100.0)	1 (100.0)	1 (100.0)
		n=122	n=11	n=2	n=0	n=0
	Biopsy	31 (25.0)	2 (18.0)	1 (50.0)	0	0
	For Surgery (excluding biopsy)	40 (33.0)	0	1 (50.0)	0	0
	Treat complication	4 (3.0)	1 (9.0)	0	0	0
	Treatment-related toxicity	0	0	0	0	0
EU5 ^a	Other	46 (38.0)	7 (64.0)	0	0	0
	Don't know	1 (1.0)	1 (9.0)	0	0	0
		n=338	n=55	n=14	n=5	n=2
	Biopsy	118 (35.0)	9 (16.0)	4 (29.0)	0	0
	For Surgery (excluding biopsy)	56 (17.0)	4 (7.0)	1 (7.0)	0	0

TW	Treat complication	68 (20.0)	22 (40.0)	3 (21.0)	2 (40.0)	0
	Treatment-related toxicity	7 (2.0)	0	0	0	0
	Other	86 (25.0)	17 (31.0)	4 (29.0)	2 (40.0)	1 (50.0)
	Don't know	3 (1.0)	3 (5.0)	2 (14.0)	1 (20.0)	1 (50.0)
		n=165	n=42	n=24	n=16	n=14
	Biopsy	102 (62.0)	7 (17.0)	1 (4.0)	1 (6.0)	0
	For Surgery (excluding biopsy)	13 (8.0)	3 (7.0)	1 (4.0)	0	0
	Treat complication	20 (12.0)	8 (19.0)	3 (13.0)	2 (12.0)	0
	Treatment-related toxicity	7 (4.0)	6 (14.0)	6 (25.0)	0	1 (7.0)
	Other	23 (14.0)	18 (43.0)	13 (54.0)	13 (81.0)	13 (93.0)
	Don't know	0	0	0	0	0
		n=140	n=49	n=19	n=9	n=6
	Biopsy	49 (35.0)	10 (20.0)	3 (16.0)	1 (11.0)	2 (33.0)
	For Surgery (excluding biopsy)	4 (3.0)	3 (6.0)	1 (5.0)	0	0
JP	Treat complication	4 (10.0)	7 (14.0)	3 (16.0)	2 (22.0)	0
	Treatment-related toxicity	62 (44.0)	27 (55.0)	9 (47.0)	5 (56.0)	2 (33.0)
	Other	11 (8.0)	2 (4.0)	3 (16.0)	1 (11.0)	2 (33.0)
	Don't know	0	0	0	0	0

All data are presented as n (%).

^aIncludes the UK, IT, FR, ES, and DE.

aNSCLC advanced non-small cell lung cancer, *BR* Brazil, *DE* Germany, *EGFR* epidermal growth factor receptor, *EQ-5D-5L* European Quality of Life 5 Dimension 5 Level, *ES* Spain, *EU5* 5 countries from the European Union, *FR* France, *IT* Italy, *JP* Japan, *TW* Taiwan, *UK* United Kingdom, *US* United States

Supplementary Table S12. Testing Performed for Advanced Diagnosis and Monitoring – Overall Population and By Country

Tests	Overall	US	BR	UK	IT	FR	ES	DE	EU5 ^a	TW	JP
Advanced diagnosis	n=2857	n=422	n=313	n=279	n=287	n=285	n=302	n=284	n=1437	n=390	n=295
Blood Tests	2367 (83.0)	323 (77.0)	224 (72.0)	222 (80.0)	198 (69.0)	260 (91.0)	279 (92.0)	267 (94.0)	1226 (85.0)	311 (80.0)	283 (96.0)
PFT	1035 (36.0)	99 (24.0)	106 (34.0)	87 (31.0)	95 (33.0)	111 (39.0)	125 (41.0)	213 (75.0)	631 (44.0)	137 (35.0)	62 (21.0)
Biopsy	2165 (76.0)	321 (76.0)	201 (64.0)	217 (78.0)	230 (80.0)	264 (93.0)	271 (90.0)	233 (82.0)	1215 (85.0)	284 (73.0)	144 (49.0)
X-Ray	1428 (50.0)	112 (27.0)	104 (33.0)	115 (41.0)	108 (38.0)	102 (36.0)	191 (63.0)	154 (54.0)	670 (47.0)	303 (78.0)	239 (81.0)
MRI	1054 (37.0)	169 (40.0)	113 (36.0)	50 (18.0)	52 (18.0)	97 (34.0)	88 (29.0)	159 (56.0)	446 (31.0)	280 (72.0)	46 (16.0)
Radioisotope/bone scan	771 (27.0)	32 (8.0)	70 (22.0)	27 (10.0)	90 (31.0)	56 (20.0)	66 (22.0)	119 (42.0)	358 (25.0)	272 (70.0)	39 (13.0)
CT-scan chest	2115 (74.0)	269 (64.0)	155 (50.0)	228 (82.0)	219 (76.0)	218 (77.0)	254 (84.0)	159 (56.0)	1078 (75.0)	340 (87.0)	273 (93.0)
Bronchoscopy	1171 (41.0)	93 (22.0)	84 (27.0)	77 (28.0)	125 (44.0)	176 (62.0)	202 (67.0)	166 (59.0)	746 (52.0)	133 (34.0)	115 (39.0)
FDG-PET scan	1401 (49.0)	255 (60.0)	128 (41.0)	103 (37.0)	160 (56.0)	230 (81.0)	172 (57.0)	43 (15.0)	708 (49.0)	146 (37.0)	164 (56.0)
Ultrasound	429 (15.0)	16 (4.0)	40 (13.0)	6 (2.0)	29 (10.0)	27 (10.0)	34 (11.0)	143 (50.0)	239 (17.0)	117 (30.0)	17 (6.0)
None of the above	111 (4.0)	4 (1.0)	41 (13.0)	20 (7.0)	19 (7.0)	3 (1.0)	12 (4.0)	4 (1.0)	58 (4.0)	6 (2.0)	2 (1.0)
Other scans and imaging	79 (3.0)	1 (<1.0)	4 (1.0)	11 (4.0)	36 (13.0)	6 (2.0)	2 (1.0)	2 (1.0)	57 (4.0)	3 (1.0)	14 (5.0)
Other tests and scales	20 (1.0)	2 (1.0)	1 (<1.0)	1 (<1.0)	7 (2.0)	1 (<1.0)	1 (<1.0)	0	10 (1.0)	7 (2.0)	0
Other scans and imaging and other tests and scales combined	99 (3.0)	3 (1.0)	5 (2.0)	12 (4.0)	43 (15.0)	7 (3.0)	3 (1.0)	2 (1.0)	67 (5.0)	10 (3.0)	16 (5.0)
Monitoring	n=2849	N=421	n=312	n=279	n=283	n=284	n=301	n=284	n=1431	n=390	n=295
Blood tests	2375 (83.0)	308 (73.0)	235 (75.0)	232 (83.0)	228 (81.0)	233 (82.0)	269 (89.0)	262 (92.0)	1224 (86.0)	337 (86.0)	271 (92.0)
PFT	482 (17.0)	70 (17.0)	89 (29.0)	12 (4.0)	42 (15.0)	14 (5.0)	20 (7.0)	181 (64.0)	269 (19.0)	47 (12.0)	7 (2.0)
Biopsy	499 (18.0)	85 (20.0)	89 (29.0)	15 (5.0)	35 (12.0)	50 (18.0)	48 (16.0)	70 (25.0)	218 (15.0)	89 (23.0)	18 (6.0)
X-Ray	982 (35.0)	45 (11.0)	76 (24.0)	59 (21.0)	54 (19.0)	63 (22.0)	86 (29.0)	84 (30.0)	346 (24.0)	302 (77.0)	213 (72.0)
MRI	603 (21.0)	78 (19.0)	100 (32.0)	24 (9.0)	38 (13.0)	39 (14.0)	36 (12.0)	75 (26.0)	212 (15.0)	194 (50.0)	19 (6.0)
Radioisotope/bone scan	401 (14.0)	32 (8.0)	48 (15.0)	12 (4.0)	42 (15.0)	10 (4.0)	18 (6.0)	35 (12.0)	117 (8.0)	193 (50.0)	11 (4.0)
CT-scan chest	1675 (59.0)	240 (57.0)	148 (47.0)	183 (66.0)	159 (56.0)	139 (49.0)	159 (53.0)	98 (35.0)	738 (52.0)	330 (85.0)	219 (74.0)
Bronchoscopy	207 (7.0)	13 (3.0)	27 (9.0)	3 (1.0)	19 (7.0)	18 (6.0)	12 (4.0)	69 (24.0)	121 (9.0)	35 (9.0)	11 (4.0)
FDG-PET scan	679 (24.0)	119 (28.0)	136 (44.0)	24 (9.0)	121 (43.0)	87 (31.0)	50 (17.0)	35 (12.0)	317 (22.0)	59 (15.0)	48 (16.0)
Ultrasound	330 (12.0)	20 (5.0)	40 (13.0)	1 (<1.0)	22 (8.0)	16 (6.0)	4 (1.0)	154 (54.0)	197 (14.0)	66 (17.0)	7 (2.0)
None of the above/don't know	104 (4.0)	18 (4.0)	22 (7.0)	14 (5.0)	16 (6.0)	12 (4.0)	9 (3.0)	1 (<1.0)	52 (4.0)	1 (<1.0)	11 (4.0)
Other scans and imaging	69 (2.0)	2 (1.0)	7 (2.0)	10 (4.0)	30 (11.0)	6 (2.0)	1 (<1.0)	2 (1.0)	49 (3.0)	2 (1.0)	9 (3.0)
Other tests and scales	11 (<1.0)	1 (<1.0)	1 (<1.0)	0	2 (1.0)	1 (<1.0)	0	0	3 (<1.0)	6 (2.0)	0
Other scans and imaging and other tests and scales combined	80 (3.0)	3 (1.0)	8 (3.0)	10 (4.0)	32 (11.0)	7 (3.0)	1 (<1.0)	2 (1.0)	52 (4.0)	8 (2.0)	9 (3.0)


All data are presented as n (%).

^aIncludes the UK, IT, FR, ES, and DE.

BR Brazil, CT computed tomography, DE Germany, FDG-PET fluorodeoxyglucose-positron emission tomography, ES Spain, EU5 5 countries from the European Union, FR France, IT Italy, JP Japan, MRI magnetic resonance imaging, TW Taiwan, UK United Kingdom, US United States

Supplementary Figures

Supplementary Figure S1. DSP™ Phases and Index Date



Development of framework:

- Protocol
- Piloting
- Physician recruitment

Clinical background including,

- Initial diagnosis of *EGFR*+ NSCLC
- treatment (e.g., neo/adjuvant treatment)
- management of early-stage NSCLC if aNSCLC is not the initial diagnosis

- Patient selection
- Data collection
- Data validation
- Final data
- Data analysis and presentation

aNSCLC advanced non-small cell lung cancer, DSP™ Disease Specific Programme™

Supplementary Figure S2. Number of Metastatic Sites – Primary and Secondary




Table below presents the number of patients evaluated for primary and secondary metastases


Country	Overall	US	BR	UK	IT	FR	ES	DE	EU5	TW	JP
Primary, n=	2396	327	233	269	246	257	295	171	1238	346	252
Secondary, n=	2415	326	242	274	247	257	295	172	1245	338	264

EU5 includes the UK, IT, FR, ES, and DE.

BR Brazil, DE Germany, ES Spain, EU European Union, FR France, IQR interquartile range, IT Italy, JP Japan, TW Taiwan, UK United Kingdom, US United States


Supplementary Figure S3. Socioeconomic Status – Overall Population

i. Employment Status – Physician and Patient Reported



All data are presented as %.

ii. Insurance coverage




All data are presented as %.

* for self-employed, unemployed, students, retired, and farm workers

NHI National Health Insurance, *PuMa* Protection Universelle Maladie, SNS Sistema Nacional de Salud

Other = Health insurance for the elderly (for over 75 years), Health insurance exchange plan, Mutual aid association (for public servants, teachers), Private Krankenversicherung, Medicaid (or equivalent in your state), Sistema Unico de Saúde (SUS), Employee provided for a small/medium enterprise (less than 300 employees), Employee provided for a large enterprise (more than 300 employees), Sistema Nacional de Salud (SNS), y seguro médico privado, Other Private, insurance covered, Private, supplementary health insurance, Tricare/Veterans health care, Seaman's Insurance, Sem cobertura do plano - Particular pago do próprio bolso, Cobra (continuation coverage), Commercial insurance only, Servizio Sanitario Nazionale & Assicurazione sanitaria private, Private self-paid, Non-Medicare retired benefit, Seguro médico privado, and Assicurazione sanitaria privata

Supplementary Figure S4. Top 10 AEs by Severity – Overall Population



All data are presented as %.

AE adverse event

Note. Percentages between 0.1% to 0.9% have been rounded off to 1.0%